Table 1 Clinical characteristics
Normal DF (n = 30) | mild LVDD (n = 51) | HFnEF (n = 49) | p-value | All (n = 130) | |
|---|---|---|---|---|---|
Clinical variables | |||||
Age (years) | 60 (50-66) | 65 (57-69) | 72 (67-76) | <0.001* | 67 (59-73) |
Female gender | 15 (50) | 21 (41) | 28 (57) | 0.278 | 64 (49) |
BMI (kg/m2) | 26 (24-32) | 27 (25-31) | 28 (25-31) | 0.236 | 27 (25-32) |
Systolic BP (mmHg) | 123 (110-130) | 130 (126-142) | 138 (130-140) | <0.001* | 130(122-140) |
Diastolic BP (mmHg) | 76 (70-80) | 80 (76-86) | 80 (70-84) | 0.023* | 80(70-83) |
CAD | 16 (53) | 31 (61) | 34 (69) | 0.346 | 81 (62) |
Previous MI | 7 (23) | 7 (14) | 14 (29) | 0.189 | 28 (22) |
Previous stroke | 0 | 2 (4) | 2 (4) | 0.339 | 4 [39] |
Previous PTCA | 14 (46) | 25 (496) | 25 (51) | 0.905 | 64 (49) |
Cardiovascular risk factors | |||||
Treated hypertension | 23 (77) | 46 (90) | 47 (96) | 0.010* | 116 (89) |
Smoking | 7 (23) | 8 (16) | 6(12) | 0.041* | 21 (16) |
Family history CAD | 15 (50) | 29 (57) | 20 (42) | 0.669* | 64 (50) |
Hyperlipidaemia | 14 (46) | 38 (74) | 33 (67) | 0.037* | 85 (65) |
Glucose metabolism status | |||||
NGT | 13 (43) | 13 (25) | 12 (24) | 0.013* | 38 (29) |
IGT | 11 (37) | 13 (25) | 10 (20) | 34 (26) | |
New detected T2DM | 3 (10) | 8 (16) | 12 (24) | 23(18) | |
Known T2DM | 3 (10) | 17 (33) | 15 (31) | 35 (29) | |
Medications | |||||
ACE inhibitor | 17 (56) | 29 (57) | 34 (69) | 0.359 | 80 (61) |
AT1 blocker | 2 (7) | 8 (16) | 11 (22) | 0.179 | 21 (16) |
Diuretics | 5 (17%) | 12 (24) | 24 (49) | 0.003* | 41 (32) |
Ca2+ blocker | 4 (13) | 6 (12) | 17 (34) | 0.011* | 27 (21) |
ß-Blocker | 21 (70%) | 32 (63) | 42 (86) | 0.032* | 95 (73) |
Insulin therapy | 0 | 8 (20) | 6 (15) | 0.128 | 14 (11) |
OAD | 1 (6) | 13 (34) | 5 (12) | 0.012* | 19 (15) |